Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia; Grupo de Investigación en Biomedicina, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia; Semillero de Investigación en Farmacología Geriátrica, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia.
Semillero de Investigación en Farmacología Geriátrica, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Pereira, Colo.
Biomedica. 2022 Jun 1;42(2):302-314. doi: 10.7705/biomedica.6116.
The inappropriate use of antibiotics is associated with a greater risk for antimicrobial resistance, high health care costs, adverse events, and worse clinical outcomes.
To determine the prescription patterns and approved and nonapproved indications for macrolides in a group of patients from Colombia.
This was a cross-sectional study on the indications for the use of macrolides in outpatients registered in a drug-dispensing database of approximately 8.5 million people affiliated with the Colombian health system. Sociodemographic, pharmacological, and clinical variables were considered.
A total of 9.344 patients had received a macrolide prescription; their median age was 40.1 years (interquartile range: 27.1-53.3 years) and 58.3% were women. The most commonly prescribed macrolide was azithromycin (38.8%) most frequently for Helicobacter pylori infection (15.9%) and pneumonia treatment (15.8%). A total of 31.3% of the prescriptions were used for unapproved indications: common cold (7.8%), COVID-19 (4.0%), and acute bronchitis (3.5%). Residence in the Caribbean region (OR=1.17; 95%CI 1.05-1.31), dental prescriptions (OR=2.75; 95%CI 1.91-3.96), presence of chronic respiratory comorbidities (OR=1.30; 95%CI 1.08-1.56), and prescription of erythromycin (OR=3.66; 95%CI 3.24-4.14) or azithromycin (OR=2.15; 95%CI 1,92-2.41) were associated with a higher probability of macrolide use for unapproved indications while being 18-64 years old (OR=0.81; 95%CI 0.71-0.93) or 65 years or older (OR=0.77; 95%CI 0.63-0.94) and residing in Bogotá-Cundinamarca (OR=0.74; 95%CI 0.65-0.85) were associated with reduced risk.
Most patients received macrolides for respiratory tract infections; erythromycin and azithromycin were used for unapproved indications in people under 18 years of age and those with chronic respiratory diseases.
抗生素的不恰当使用与抗菌药物耐药性风险增加、医疗保健费用高、不良事件和临床结局恶化有关。
确定一组来自哥伦比亚的患者使用大环内酯类药物的处方模式和批准及未批准的适应证。
这是一项关于在大约 850 万与哥伦比亚卫生系统有关联的人群中,使用大环内酯类药物的适应证的门诊患者的药物配给数据库的横断面研究。考虑了社会人口统计学、药理学和临床变量。
共有 9344 名患者接受了大环内酯类药物的处方;他们的中位年龄为 40.1 岁(四分位距:27.1-53.3 岁),58.3%为女性。最常开的大环内酯类药物是阿奇霉素(38.8%),最常用于治疗幽门螺杆菌感染(15.9%)和肺炎(15.8%)。共有 31.3%的处方用于未经批准的适应证:普通感冒(7.8%)、COVID-19(4.0%)和急性支气管炎(3.5%)。居住在加勒比地区(OR=1.17;95%CI 1.05-1.31)、牙科处方(OR=2.75;95%CI 1.91-3.96)、存在慢性呼吸道合并症(OR=1.30;95%CI 1.08-1.56)和处方红霉素(OR=3.66;95%CI 3.24-4.14)或阿奇霉素(OR=2.15;95%CI 1.92-2.41)与大环内酯类药物用于未经批准的适应证的可能性增加相关,而 18-64 岁(OR=0.81;95%CI 0.71-0.93)或 65 岁或以上(OR=0.77;95%CI 0.63-0.94)和居住在波哥大-昆迪纳马卡(OR=0.74;95%CI 0.65-0.85)与降低风险相关。
大多数患者因呼吸道感染而接受大环内酯类药物治疗;18 岁以下人群和患有慢性呼吸道疾病的人群使用红霉素和阿奇霉素治疗未经批准的适应证。